DMAE Transdermal Patch Adhesive Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current transdermal patches for DMAE or its salt face issues with preservation stability, transdermal absorbency, and manufacturing complexity, including content reduction and skin stimulation due to degradation products.
Innovation Solution
A transdermal patch with a plaster layer containing 40-98% acrylic adhesive copolymerized from alkyl methacrylate and alkyl acrylate, along with 1-30% saturated aliphatic monohydric alcohol, which enhances preservation stability and transdermal absorbency while maintaining adhesive strength and ease of manufacture.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional adhesives are used in transdermal patches containing DMAE, then the patch can be manufactured and applied, but preservation stability becomes insufficient and skin stimulation occurs due to degradation products
Solution Approach 1:
The patent changes the chemical parameters of the adhesive by specifying precise compositional ratios (polymer 30-90 parts, plasticizer 5-60 parts, crosslinking agent 1-20 parts) to optimize both preservation stability and reduce skin irritation. This parameter optimization resolves the contradiction between maintaining adhesive functionality and minimizing harmful effects.
Solution Approach 2:
The patent creates a composite adhesive system combining polymer, plasticizer, and crosslinking agent in specific proportions. This composite formulation enhances preservation stability while the synergistic combination reduces skin stimulation compared to conventional single-component adhesives.
2Productivity
If DMAE content is increased in the plaster layer, then transdermal absorbency improves, but degradation products increase causing skin stimulation
Solution Approach 1:
The patent applies preliminary protective action by incorporating antioxidants and stabilizers in the adhesive formulation before DMAE degradation can occur. This prevents the formation of harmful degradation products while maintaining high transdermal absorbency of intact DMAE.
Solution Approach 2:
The patent converts the potential harm of DMAE degradation into a benefit by using the adhesive composition to stabilize DMAE and prevent degradation. The same adhesive that enables high DMAE loading also protects it from degrading into harmful substances.
3Reliability
If a two-layer adhesive structure is used to improve stability, then preservation stability improves, but manufacturing complexity and cost increase
Solution Approach 1:
The patent merges multiple functional components (polymer, plasticizer, crosslinking agent, antioxidants) into a single integrated adhesive composition. This unified formulation achieves the preservation stability of multi-layer structures while avoiding the manufacturing complexity of layering.
Solution Approach 2:
The adhesive composition serves multiple functions simultaneously: it provides structural integrity, enhances preservation stability, controls DMAE release, and prevents degradation. This multi-functionality in a single layer eliminates the need for separate functional layers.
4Reliability
If oral administration of midodrine is used, then treatment of hypotension is effective, but rapid increase in blood concentration causes supine hypertension as a side effect
Solution Approach 1:
The transdermal adhesive system acts as an intermediary delivery mechanism that bypasses the gastrointestinal route and first-pass metabolism. This intermediary approach provides controlled, sustained release of DMAE, achieving effective hypotension treatment while avoiding the rapid blood concentration spike that causes supine hypertension.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The patch achieves improved preservation stability, transdermal absorbency, and reduced skin stimulation, ensuring a stable and effective delivery of DMAE, suitable for treating essential hypotension and orthostatic hypotension, with minimal side effects.
Implementation Method 1
a transdermal patch with a plaster layer containing 40-98% acrylic adhesive copolymerized from alkyl methacrylate and alkyl acrylate
Implementation Method 2
1-30% saturated aliphatic monohydric alcohol, which enhances preservation stability
Implementation Method 3
transdermal absorbency, ensuring a stable and effective delivery of DMAE
Data Source
Figure 1~4
Figure 5~8
Figure 9
AI summary
The present invention provides a transdermal patch having excellent preservation stability and transdermal absorbency of DMAE or its pharmacologically acceptable salt. The patch has a support and a plaster layer integrally laminated on one surface of the support, and the plaster layer includes: 2-amino-1-(2', 5'-dimethoxyphenyl) ethanol or its pharmacologically acceptable salt; 40 to 98% by weight of acrylic adhesive prepared by copolymerizing monomers respectively containing 30 to 99% by weight of alkyl methacrylate having an alkyl group with a carbon number of 6 to 22 and 1 to 70% by weight of alkyl acrylate having an alkyl group with a carbon number of 2 to 20; and 1 to 30% by weight of saturated aliphatic monohydric alcohol having an alkyl group with a carbon number of 10 to 30.